Side-by-side · Research reference
ProstamaxvsPT-141
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AAnimal-MechanisticHUMAN-REVIEWED11/38 cited
BFDA-ApprovedHUMAN-REVIEWED13/41 cited
Prostamax
Khavinson Bioregulator · Tissue-Specific Peptide
4 AAPeptide length
SQ · Protocol per Khavinson tradition
PT-141
MC4R Agonist · FDA-Approved (HSDD)
SQ · Abdomen / thigh · ≥45 min before sex
01Mechanism of Action
Parameter
Prostamax
PT-141
Primary target
Chromatin in prostatic cells — pericentromeric heterochromatin regions
Melanocortin-4 receptor (MC4R) in hypothalamusSimerly 2023VYLEESI (bremelanotide injecti 2019
Pathway
Epigenetic modulation → heterochromatin decondensation → transcriptional derepressionDzhokhadze 2012
MC4R agonism in paraventricular nucleus → autonomic + neuroendocrine sexual arousal pathwaysSimerly 2023
Downstream effect
Increased sister chromatid exchange, Ag-NOR activation, reduced C-heterochromatin condensation; tissue-specific regenerative stimulation in prostate organotypic culturesDzhokhadze 2012Zakutskiĭ 2006
Increased sexual desire and arousal; central rather than peripheral mechanismClayton 2015
Feedback intact?
—
—
Origin
Synthetic tetrapeptide modeled on naturally occurring protein-derived bioregulators isolated between lysine-arginine motifs in long-lived speciesKhavinson 2017
Cyclic 7-AA peptide derived from α-MSH (agonist Ac-Nle-Asp-His-D-Phe-Arg-Trp-Lys-OH cyclic)VYLEESI (bremelanotide injecti 2019
Antibody development
—
—
02Dosage Protocols
Parameter
Prostamax
PT-141
Effective concentration (in vitro)
0.05 ng/mLZakutskiĭ 2006
Organotypic culture model; demonstrated tissue-specific stimulation.
—
Human clinical dose
Not established
No published human trials; dosing extrapolated from Russian clinical tradition (not peer-reviewed).
—
Evidence basis
Animal / organotypic cultureZakutskiĭ 2006Dzhokhadze 2012
No randomized controlled trials in humans.
FDA-approved (HSDD pre-menopausal women)VYLEESI (bremelanotide injecti 2019Clayton 2015
Age groups studied
Young (3-week) and aged (18-month) rats; elderly humans (75–86 years) in vitroZakutskiĭ 2006Dzhokhadze 2012
—
Duration
Not specified
Khavinson protocols typically 10–20 days per cycle; no long-term safety data.
PRN; reassess if no benefit after 8 doses
Standard dose
—
1.75 mg SQVYLEESI (bremelanotide injecti 2019
Single dose ≥45 min before anticipated sexual activity. Max 1 dose / 24 hr.
Frequency
—
PRN, max 8 doses / month
Lower / starter dose
—
1 mg (off-label)
Reconstitution
—
Pre-filled commercial pen (Vyleesi). Research vial: bacteriostatic water.
Timing
—
≥45 min before sexual activity
04Side Effects & Safety
Parameter
Prostamax
PT-141
Published adverse events
None reported in available literature
—
Genotoxicity signals
Increased sister chromatid exchange (SCE) — marker of DNA recombination/repair; unclear long-term implications
—
Metal ion interactions
Modulates Cu(II) and Cd(II) chromatin effects; unknown clinical relevance
—
Human safety data
Absent — no published Phase 1/2/3 trials
—
Flushing
—
Common, transient
Injection site reaction
—
Erythema, mild pain
Headache
—
Common
Hyperpigmentation (focal)
—
Rare focal skin darkening; reversible after discontinuationVYLEESI (bremelanotide injecti 2019
Hypertension (transient)
—
Mean ↑6 mmHg systolic peaking ~4 h post-dose; resolves within 12 hVYLEESI (bremelanotide injecti 2019
Pregnancy / OB
—
Contraindicated
Cardiovascular disease
—
Use caution; transient BP rise
Absolute Contraindications
Prostamax
- ·Active prostate malignancy — epigenetic modulation effects unknown in cancer
PT-141
- ·Uncontrolled hypertension
- ·Known cardiovascular disease (caution)
- ·Pregnancy
Relative Contraindications
Prostamax
- ·History of prostate cancer — theoretical concern re: transcriptional activation
- ·Undiagnosed prostatic nodules or elevated PSA
PT-141
- ·Pre-existing hyperpigmentation disorders
- ·MC4R-pathway-dependent psychiatric conditions
05Administration Protocol
Parameter
Prostamax
PT-141
1. Route
Subcutaneous or intramuscular — per Khavinson bioregulator tradition. No published human pharmacokinetic data.
Vyleesi: pre-filled auto-injector. Research vial: 2 mL bacteriostatic water per 10 mg → 5 mg/mL.
2. Reconstitution
If lyophilised: reconstitute with sterile water per manufacturer protocol (not standardized in literature).
SQ — abdomen or thigh.
3. Frequency
Typically daily or every-other-day in Russian clinical tradition; duration 10–20 days per cycle.
≥45 min before sexual activity for peak effect. Effect persists ~6–8 h.
4. Monitoring
No established biomarkers. Theoretical: PSA, prostate imaging, symptom scores (IPSS for BPH).
Vyleesi: room temp ≤30 °C. Research vial: refrigerate after reconstitution.
5. Note
All protocols derived from non-peer-reviewed Russian clinical practice; Western regulatory approval absent.
Auto-injector (Vyleesi) or 29–31G, 4–8 mm insulin syringe.